GT20029 Androgenic Alopecia Trial
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read More
China Trial Enrolls 180 Patients To Complete Enrollment: Update (8/22/23) On August 22, 2023, Kintor Pharmaceutical announced the completion of patient enrollment in a phase 2 trial in China for GT20029. This means all of the patients needed to complete the study have been enrolled, and will undergo their dosing schedule over the next 12…
Read More